UNSPSC 51111833: Axitinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H18N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9LVQ0YUXG. European Medicines Agency schedules axitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25427. The term AXITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule axitinib under HS 29333990 and SITC 51574.

As of Q4 2014, AXITINIB remains the US FDA Preferred Term for this commodity. Axitinib bears US NLM identifiers UMLS ID C1700874 and NCI Concept Code C38718. SMILES: S(C1CC2[NH]NC(C2CC1)/C=C/C1NCCCC1)C1C(CCCC1)C(=O)NC.

UNSPSC 51111833 Axitinib is a Commodity code covering a specific pharmaceutical active ingredient used in cancer treatment, but the recent state and local procurement activity under this code reflects broader generic and over-the-counter pharmaceutical supply arrangements rather than axitinib specifically. State and local governments buy multi-source generic pharmaceuticals and OTC products through cooperative purchasing agreements, with manufacturers and wholesalers competing on pricing, product availability, compliance with FDA and Drug Supply Chain Security Act (DSCSA) standards, and logistics capability. The issuing bodies are primarily multistate cooperative purchasing alliances administering agreements on behalf of participating state agencies, counties, municipalities, and other public facilities. Vendors must maintain current Good Manufacturing Practices (cGMP) certification, establish relationships with designated pharmaceutical wholesalers, support electronic data interchange (EDI) ordering, and carry substantial liability insurance ($5 million commercial general liability per occurrence minimum).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon. The solicitation is due March 26, 2026, with questions closing February 18, 2026 and contract awards effective July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with the remainder distributed across fixed pricing (10 percent), price format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain relationships with at least two of the three. The contract term is two years for new vendors, with optional extensions, and incumbent responders' amendments extend through June 30, 2028.